Ogbonna Ogbu, MD
Critical Care Medicine · Stockbridge, GANPI 1184883985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $850, 3.1 times the $274 reported in 2019.
Across 148 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$590
- Insmed, Inc.$292
- AstraZeneca$290
- Regeneron Healthcare Solutions, Inc.$223
- Boehringer Ingelheim$205
- Mylan Specialty L.p.$122
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,98098%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 31 | $590 |
| Insmed, Inc. | 12 | $292 |
| AstraZeneca(2 entities) | 15 | $290 |
| Regeneron Healthcare Solutions, Inc. | 11 | $223 |
| Boehringer Ingelheim | 12 | $205 |
| Mylan Specialty L.p. | 6 | $122 |
| Grifols USA, LLC | 5 | $96 |
| Philips North America LLC | 4 | $90 |
| Mallinckrodt Enterprises LLC | 3 | $86 |
| Advanced Respiratory, Inc | 4 | $82 |
| Neurelis, Inc. | 4 | $79 |
| Baxter Healthcare | 4 | $77 |
| Mallinckrodt Hospital Products Inc. | 1 | $75 |
| Pfizer | 3 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Resmed Corp | 4 | $65 |
| Upsher-smith Laboratories LLC | 3 | $57 |
| Fisher & Paykel Healthcare Inc | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 3 | $51 |
| Inari Medical, Inc. | 1 | $41 |
| Caris MPI, Inc. | 1 | $31 |
| Verona Pharma, Inc. | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $30 |
| Bayer | 1 | $23 |
| Amgen | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $20 |
| Sanofi | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Gilead | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Ambu Inc. | 1 | $10 |
How this compares
$3,055 in reported general payments places this provider in the 80th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 169 | $125,082 |
| Fasenra PenBenralizumab | 13 | $70,985 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $29,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $22,300 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $17,767 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $16,385 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,717 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,095 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 231 | $7,823 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,189 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $2,975 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,300 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,346 |
| Montelukast Sodium | 34 | $248 |
| Levocetirizine Dihydrochloride | 27 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $590 | $167,284269 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $290 | $31,39559 claims |
| Boehringer IngelheimStiolto Respimat | $205 | $16,38533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Stockbridge
- Asharul UsmaniStockbridge$9K
- Khushboo ChokshiStockbridge$4K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
- Matthew SchmittAtlanta$32K
- Prasad GarimellaBraselton$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.